Treatment of Uterine Sarcoma in High-Grade Uterine Adenosarcoma with Sarcomatous Overgrowth
High-grade uterine adenosarcoma with sarcomatous overgrowth is managed with chemotherapy consistent with the approach used for other high-grade uterine sarcomas, reflecting similar efficacy across these variants.
Clinical scenario
This protocol addresses patients with high-grade uterine adenosarcoma with sarcomatous overgrowth — a setting in which systemic chemotherapy is the established primary modality, aligned with management principles for high-grade uterine sarcomas more broadly.
Treatment approach
Systemic chemotherapy is central to management, with the specific agent or combination selected based on prior treatment history.
Full regimen details, sequencing, and agent selection criteria are in the structured protocol below.
References
DOI: 10.1136/ijgc-2024-005823
High-grade sarcomas should be managed with chemotherapy, similar to the approach in other high-grade uterine sarcomas due to similar efficacy with options including doxorubicin as a single agent or combined with ifosfamide.
Systemic therapy options include doxorubicin (II, B) or gemcitabine as a single agent or in combination with docetaxel (III, B); high dose ifosfamide (continuous infusion), trabectedin, or pazopanib as single agents (IV, C). The choice depends on the agent used in the first-line setting.
View source ↗